

Table S1. Baseline demographics and disease characteristics

Parameter	Patients receiving alemtuzumab (N = 304)
Age, y, mean (SD)	46.9 (11.2)
Female, n (%)	209 (68.8)
Race, n (%)	
White	261 (85.9)
Black or African American	36 (11.8)
Asian	1 (0.3)
Other/missing	6 (2.0)
Ethnicity, n (%)	
Hispanic or Latino	26 (8.6)
Not Hispanic or Latino	242 (79.6)
Unknown/missing	36 (11.8)
Time since first diagnosis, y, mean (SD)	10.5 (7.3)
No. of relapses in prior 2 y, mean (SD) ^a	1.1 (1.4)
No. of relapses in prior 2 y, n (%) ^a	
0	131 (43.7)
1	78 (26.0)
2	55 (18.3)
3	20 (6.7)
4	9 (3.0)
≥5	7 (2.3)
Patients with history of other therapies in 2 y prior to alemtuzumab, n (%)	294 (96.7)
Disease-modifying therapies used prior to alemtuzumab, n (%) ^b	
Natalizumab	170 (55.9)
Fingolimod	71 (23.4)
Dimethyl fumarate	66 (21.7)
Teriflunomide	32 (10.5)
Glatiramer acetate	26 (8.6)
Interferon beta-1b	24 (7.9)
Interferon beta-1a subcutaneous	22 (7.2)
Interferon beta-1a intramuscular	11 (3.6)
PEGylated interferon beta-1a	9 (3.0)
Rituximab	5 (1.6)
Others	4 (1.3)

^aN = 300.

^bPatients may have received more than one prior therapy.

Table S2. Changes from pre-course baseline during infusions ≥4 hours

Infusion hour	Patients receiving alemtuzumab (N = 304)					
	No. of patients	Change from precourse baseline, mean (SD)				
		Systolic BP, mm Hg	Diastolic BP, mm Hg	Heart rate, bpm	Respiratory rate, breaths/min	Temperature, °C
Day 1						
Hour 4	255	0.45 (15.22)	-3.32 (11.15)	19.71 (14.37)	0.36 (1.90) ^a	0.24 (0.56) ^a
Hour 5	12	-4.50 (11.21)	-9.17 (12.52)	15.33 (18.23)	0.82 (1.33) ^b	0.40 (0.63) ^b
Hour 6	3	4.00 (10.58)	-7.67 (9.50)	23.33 (13.58)	3.00 (1.41) ^c	1.10 (0.42) ^c
Day 2						
Hour 4	244	-0.34 (15.25)	-3.47 (11.65)	6.10 (11.48)	-0.05 (2.08) ^d	0.15 (0.44) ^e
Hour 5	6	7.00 (15.81)	-1.00 (10.41)	2.17 (11.79)	1.00 (1.67)	0.25 (0.23)
Day 3						
Hour 4	242	6.12 (17.47)	0.50 (11.96)	-0.43 (12.35) ^f	-0.04 (2.11) ^g	0.08 (0.43) ^h
Hour 5	5	18.20 (19.15)	8.40 (21.87)	1.20 (4.32)	-0.40 (0.89)	0.08 (0.33)
Hour 6	2	17.00 (16.97)	3.00 (22.63)	2.50 (4.95)	0.00 (0.00)	0.15 (0.35)
Hour 8	1	23.00	19.00	-3.00	-2.00	-0.10
Day 4						
Hour 4	240	5.24 (18.22)	0.68 (12.27)	-0.88 (13.66)	0.04 (1.99) ⁱ	0.10 (0.43) ^e
Hour 5	7	9.14 (13.99)	-0.43 (13.70)	-2.14 (14.29)	0.17 (0.98) ^j	-0.03 (0.36)
Hour 6	3	-0.33 (4.51)	-8.33 (4.73)	-4.33 (18.23)	0.00 (0.00)	-0.10 (0.36)
Hour 8	1	38.00	17.00	8.00	2.00	-0.10
Day 5						
Hour 4	231	3.65 (16.09)	0.65 (11.52)	1.80 (12.32)	-0.04 (2.34) ^k	0.11 (0.47) ^l
Hour 5	6	4.33 (14.76)	-1.50 (10.19)	1.33 (11.59)	0.80 (1.10) ^m	0.08 (0.49)
Hour 6	1	-13.00	-10.00	9.00	2.00	-0.40

Abbreviations: BP, blood pressure; bpm, beats per minute.

^aN = 241; ^bN = 11; ^cN = 2; ^dN = 236; ^eN = 231; ^fN = 240; ^gN = 228; ^hN = 229; ⁱN = 230; ^jN = 6; ^kN = 219; ^lN = 220; ^mN = 5.

Figure S1. Patient disposition flowchart

^a33 patients completed the treatment within 8-30 days of first infusion and 2 patients received 4 days of treatment.

